Related Experiment Video
Updated: Jun 18, 2026

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Published on: July 12, 2011
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
K S Ginsburg1, M H Liang, L Newcomer
1Department of Rheumatology and Immunology, Brigham and Women's Hospital, Boston, MA 02115.
Insights
Elevated anticardiolipin antibodies are a significant risk factor for venous thrombosis and pulmonary embolism in men. However, anticardiolipin antibodies do not appear to increase the risk of ischemic stroke in this population.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Immunology
Background:
- Anticardiolipin antibodies (aCL) are associated with an increased risk of thrombosis.
- The role of aCL as a risk factor for specific thrombotic events like ischemic stroke and venous thromboembolism (VTE) requires further elucidation in healthy populations.
Purpose of the Study:
- To investigate whether anticardiolipin antibodies are a risk factor for ischemic stroke and venous thrombosis in healthy adult men.
Main Methods:
- A nested case-control study was conducted within the prospective Physicians' Health Study cohort.
- Plasma samples from 22,071 male physicians were analyzed for IgG anticardiolipin antibodies using ELISA.
- Conditional logistic regression was used to calculate relative risks for VTE and ischemic stroke based on aCL antibody titers.
Main Results:
- Higher anticardiolipin antibody titers were observed in patients with deep venous thrombosis or pulmonary embolism compared to controls (P=0.01).
- Individuals with aCL antibody titers above the 95th percentile had a 5.3-fold increased risk of developing deep venous thrombosis or pulmonary embolism (P=0.01).
- No significant difference in aCL antibody titers was found between patients with ischemic stroke and controls, indicating no clear association.
Conclusions:
- Anticardiolipin antibody levels above the 95th percentile are a significant risk factor for venous thromboembolism (deep venous thrombosis or pulmonary embolism) in healthy men.
- Anticardiolipin antibodies are not identified as a risk factor for ischemic stroke in this cohort of healthy adult men.
Objective:
To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men.
Design:
A nested, case-control study in a prospective cohort.
Setting:
A nationwide study of physicians.
Participants:
The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22,071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80 degrees C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus.
Measurements:
Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression.
Results:
The anticardiolipin antibody titers were higher in case patients with deep venous thrombosis and pulmonary embolus than in their matched controls (P = 0.01). Persons with anticardiolipin antibody titers above the 95th percentile had a relative risk for developing deep venous thrombosis or pulmonary embolus of 5.3 (95% CI, 1.55 to 18.3; P = 0.01). The anticardiolipin antibody titers in case patients with ischemic stroke and controls were not significantly different (P > 0.2), and no clear trend of higher risks among those with elevated levels of anticardiolipin antibodies was observed.
Conclusion:
An anticardiolipin antibody level above the 95th percentile is an important risk factor for deep venous thrombosis or pulmonary embolus but not for ischemic stroke in healthy adult men.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction

